Table 1.
Ref. | Süleymanlar et al[26] (1998) | Gürsoy et al[27] (2001) | Urbánek et al[28] (2004) | Al-Harbi et al[29] (2005) | Rocha et al[30](2007) | Engel et al[32](2007) | Liu et al[33](2010) | Ferreira et al[31] (2011) |
n | 3 | 36 | 18 | 9 | 23 | 10 | 35 | 26 |
Interferon type | IFN | IFN | IFN | IFN | IFN | PEG-IFN α2b | PEG-IFN α2a | IFN |
PEG-IFN α2a | ||||||||
Schedule | 4.5 MU tiw | 3 MU or | 10 MU + | 3 MU tiw | 3 MU or | 1 μg/kg qw | 135 μgv qw | 3 MU tiw |
6-10 MU tiw | 3 MU tiw | 6 MU tiw | or 135 μg qw | |||||
Duration | 16 wk | 12 wk | 3 wk + 12 wk | 12 wk | 48 or 24 wk | 24 wk | 24 wk | 48 wk |
SVR | 100% | 39% | 72% | 67% | 43% | 40% | 89% | 54% |
IFN: Interferon; PEG-IFN: Pegylated interferon; MU: Million units; tiw: Three times a week; qw: Once a week; SVR: Sustained virological response rate by intention-to-treat analysis.